We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Brain metastases in patients with salivary duct carcinoma: A retrospective study.
- Authors
Fushimi, Chihiro; Takahashi, Hideaki; Kawakita, Daisuke; Kano, Satoshi; Tsukahara, Kiyoaki; Ozawa, Hiroyuki; Okami, Kenji; Sakai, Akihiro; Yamazaki, Keisuke; Okada, Takuro; Hanazawa, Toyoyuki; Sato, Yuichiro; Imanishi, Yorihisa; Shimizu, Akira; Matsuki, Takashi; Nagao, Toshitaka; Tada, Yuichiro
- Abstract
Background: Salivary duct carcinoma (SDC) is a high‐grade adenocarcinoma with a 5‐year survival rate of 40%. Although drug therapy has improved patients' prognosis, the impact of brain metastasis (BM) remains poorly understood. We aimed to retrospectively examine the incidence of BM in patients with SDC (n = 464) and develop a tool to estimate their prognoses. Methods: We retrospectively examined 464 patients with SDC enrolled in a multicenter study. We investigated the incidence of BM, overall survival (OS) rates, and factors affecting prognosis in patients with BM. We also developed an SDC‐graded prognostic assessment (GPA) score for disease prognostication. Results: Sixty‐five (14%) patients had BM. The median OS (mOS) was 13.1 months. On univariate and multivariate analyses, factors such as Eastern Cooperative Oncology Group Performance Status >1, human epidermal growth factor receptor 2‐negative status, and locoregional uncontrolled disease were associated with poor OS. SDC‐GPA scores according to the prognostic factors were 0, 1, 2, and 3 points, and mOS estimates were 50.5, 16.1, 3.9, and 1.2 months, respectively (p < 0.001). Conclusion: The SDC‐GPA score emerged as a useful prognostication tool for patients with BM.
- Subjects
BRAIN metastasis; EPIDERMAL growth factor receptors
- Publication
Cancer Medicine, 2024, Vol 13, Issue 5, p1
- ISSN
2045-7634
- Publication type
Article
- DOI
10.1002/cam4.7037